Primer Myelofibrozis Tedavisi

Kaynaklar:

1- Tefferi A, Guglielmelli P, Pardanani A, Vannucchi AM. Myelofibrosis Treatment Algorithm 2018. Blood Cancer J. 2018 Jul 31. 8 (8):72. 

2-Tefferi A, Guglielmelli P, Nicolosi M, Mannelli F, Mudireddy M, Bartalucci N, et al. GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis. Leukemia. 2018 Jul. 32 (7):1631-1642. 

3-Levine RL, Belisle C, Wadleigh M, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006 May 15. 107(10):4139-41. 

4-Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar 19-25. 365(9464):1054-61. 

5-Barosi G, Marchetti M, Massa M et al. Incidence and clinical profile of JAK2 V617F mutation in myelofibrosis with myeloid metaplasia [abstract]. Blood. November 2005. 106:a256. 

6-Barosi G, et al, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia. 2008 Feb. 22 (2):437-8. 

7-[Guideline] NCCN Clinical Practice Guidelines in Oncology: Myeloproliferative Neoplasms. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/mpn.pdf. Version 1.2020 — May 21, 2020; Accessed: February 2, 2021.

8-Kröger NM, Deeg JH, Olavarria E, Niederwieser D, Bacigalupo A, et al. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group. Leukemia. 2015 Nov. 29 (11):2126-33. 

9-Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 Mar 1. 366(9):799-807. 

10-Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 Mar 1. 366(9):787-98. 

11-Pardanani A, Harrison C, Cortes JE, Cervantes F, Mesa RA, Milligan D, et al. Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. JAMA Oncol. 2015 Aug. 1 (5):643-51. 

12-Gilbert HS. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy. Cancer. 1998 Sep 15. 83(6):1205-13.